| Kirsten Taleb, NP | |
|
533 Jermor Ln, Westminster, MD 21157-6126 | |
| (434) 952-7798 | |
| Not Available |
| Full Name | Kirsten Taleb |
|---|---|
| Gender | Female |
| Speciality | Nurse Practitioner |
| Experience | 5 Years |
| Location | 533 Jermor Ln, Westminster, Maryland |
| Accepts Medicare Assignments | Yes. She accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1225675465 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 363LF0000X | Nurse Practitioner - Family | R207405 (Maryland) | Primary |
| Entity Name | U N I Medical Care Inc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1790962371 PECOS PAC ID: 7517035611 Enrollment ID: O20081002000257 |
News Archive
EMIT Corporation announced today that it has received CE-Mark for its HypothermX Intravenous Fluid and Blood Warming Devices with sterile fluid paths, allowing for sales expansion into the European and other OUS markets.
An exciting new study describes a specific inhibitor of the SARS-CoV-2 found in an extract of the common dandelion that could provide a new and fruitful avenue of drug research.
Nuon Therapeutics, Inc., a privately held, clinical stage biopharmaceutical company, announced that the company is advancing its lead program, NU1618, into phase 2b development for the treatment of chronic hyperuricemia in patients with gout. Nuon anticipates releasing topline data from a completed proof-of-principle, phase 2a study of NU1618 in the second quarter of 2010.
HemoShear LLC, a biotechnology research company and leading developer of human cell-based surrogate systems for discovery and assessment of new drug compounds, today announced that the U.S. Patent and Trademark Office (USPTO) has granted it patent no. 7,811,782 entitled "Use of An In Vitro Hemodynamic Endothelial/Smooth Muscle Cell Co-Culture Model to Identify New Therapeutic Targets for Vascular Disease."
› Verified 5 days ago
| Entity Name | A Clean Start Llc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1194295881 PECOS PAC ID: 9931508124 Enrollment ID: O20210520000015 |
News Archive
EMIT Corporation announced today that it has received CE-Mark for its HypothermX Intravenous Fluid and Blood Warming Devices with sterile fluid paths, allowing for sales expansion into the European and other OUS markets.
An exciting new study describes a specific inhibitor of the SARS-CoV-2 found in an extract of the common dandelion that could provide a new and fruitful avenue of drug research.
Nuon Therapeutics, Inc., a privately held, clinical stage biopharmaceutical company, announced that the company is advancing its lead program, NU1618, into phase 2b development for the treatment of chronic hyperuricemia in patients with gout. Nuon anticipates releasing topline data from a completed proof-of-principle, phase 2a study of NU1618 in the second quarter of 2010.
HemoShear LLC, a biotechnology research company and leading developer of human cell-based surrogate systems for discovery and assessment of new drug compounds, today announced that the U.S. Patent and Trademark Office (USPTO) has granted it patent no. 7,811,782 entitled "Use of An In Vitro Hemodynamic Endothelial/Smooth Muscle Cell Co-Culture Model to Identify New Therapeutic Targets for Vascular Disease."
› Verified 5 days ago
| Entity Name | Our Family Healthcare |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1740937366 PECOS PAC ID: 6204210545 Enrollment ID: O20220906000373 |
News Archive
EMIT Corporation announced today that it has received CE-Mark for its HypothermX Intravenous Fluid and Blood Warming Devices with sterile fluid paths, allowing for sales expansion into the European and other OUS markets.
An exciting new study describes a specific inhibitor of the SARS-CoV-2 found in an extract of the common dandelion that could provide a new and fruitful avenue of drug research.
Nuon Therapeutics, Inc., a privately held, clinical stage biopharmaceutical company, announced that the company is advancing its lead program, NU1618, into phase 2b development for the treatment of chronic hyperuricemia in patients with gout. Nuon anticipates releasing topline data from a completed proof-of-principle, phase 2a study of NU1618 in the second quarter of 2010.
HemoShear LLC, a biotechnology research company and leading developer of human cell-based surrogate systems for discovery and assessment of new drug compounds, today announced that the U.S. Patent and Trademark Office (USPTO) has granted it patent no. 7,811,782 entitled "Use of An In Vitro Hemodynamic Endothelial/Smooth Muscle Cell Co-Culture Model to Identify New Therapeutic Targets for Vascular Disease."
› Verified 5 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Kirsten Taleb, NP 533 Jermor Ln, Westminster, MD 21157-6126 Ph: () - | Kirsten Taleb, NP 533 Jermor Ln, Westminster, MD 21157-6126 Ph: (434) 952-7798 |
News Archive
EMIT Corporation announced today that it has received CE-Mark for its HypothermX Intravenous Fluid and Blood Warming Devices with sterile fluid paths, allowing for sales expansion into the European and other OUS markets.
An exciting new study describes a specific inhibitor of the SARS-CoV-2 found in an extract of the common dandelion that could provide a new and fruitful avenue of drug research.
Nuon Therapeutics, Inc., a privately held, clinical stage biopharmaceutical company, announced that the company is advancing its lead program, NU1618, into phase 2b development for the treatment of chronic hyperuricemia in patients with gout. Nuon anticipates releasing topline data from a completed proof-of-principle, phase 2a study of NU1618 in the second quarter of 2010.
HemoShear LLC, a biotechnology research company and leading developer of human cell-based surrogate systems for discovery and assessment of new drug compounds, today announced that the U.S. Patent and Trademark Office (USPTO) has granted it patent no. 7,811,782 entitled "Use of An In Vitro Hemodynamic Endothelial/Smooth Muscle Cell Co-Culture Model to Identify New Therapeutic Targets for Vascular Disease."
› Verified 5 days ago
Faye L Koerner, CRNP Nurse Practitioner Medicare: Not Enrolled in Medicare Practice Location: 247 E Main St, Westminster, MD 21157 Phone: 443-289-8149 Fax: 443-821-3280 | |
Denise Sirenne, CRNP Nurse Practitioner Medicare: Not Enrolled in Medicare Practice Location: 200 Memorial Avenue, Carroll Hospital Center, Westminster, MD 21157 Phone: 410-871-6157 Fax: 410-871-7199 | |
Erica Lynn Gifford, FNP-C Nurse Practitioner Medicare: Accepting Medicare Assignments Practice Location: 410 Malcolm Dr Ste C, Westminster, MD 21157 Phone: 410-857-2300 Fax: 410-367-2048 | |
Mrs. Suzanne Cerrone, AGPCNP-BC Nurse Practitioner Medicare: Medicare Enrolled Practice Location: 1812 Baltimore Blvd Ste F, Westminster, MD 21157 Phone: 410-871-0201 | |
Dr. Marjorie Simpson, PHD, CRNP Nurse Practitioner Medicare: Accepting Medicare Assignments Practice Location: Po Box 973, Westminster, MD 21158 Phone: 410-218-4786 Fax: 410-795-0029 | |
Bridget Turner, Nurse Practitioner Medicare: Not Enrolled in Medicare Practice Location: 511 Jermor Ln, Westminster, MD 21157 Phone: 410-871-1000 | |
Mrs. Margaret Dermer, CRNP Nurse Practitioner Medicare: Accepting Medicare Assignments Practice Location: 1011 Baltimore Blvd, Westminster, MD 21157 Phone: 410-857-8536 Fax: 410-848-1178 |